| Neurocrine Biosciences is a commercial-stage biopharmaceutical company focused on discovering and developing treatments for patients with neurological, endocrine and psychiatric disorders. Co. is primarily focused on the commercialization of INGREZZA® (valbenazine) in the United States. Co.'s late-stage pipeline includes opicapone as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients, elagolix for the treatment of heavy menstrual bleeding associated with uterine fibroids in women, valbenazine for the treatment of chorea in adult patients with Huntington's disease and NBIb-1817 (VY-AADC) for the treatment of Parkinson's disease patients. We show 46 historical shares outstanding datapoints in our coverage of NBIX's shares outstanding history.|
Understanding the changing numbers of NBIX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NBIX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NBIX by allowing them to research NBIX shares outstanding history
as well as any other stock in our coverage universe.